Insulin administration may trigger pancreatic beta-cell destruction in patients with type 2 diabetes

Mai Nakamura1, Wataru Nishida, Yuya Yamada

  • 1Department of Molecular and Genetic Medicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime 791-0295, Japan.

Insights

Human insulin therapy may trigger pancreatic beta-cell destruction in patients with type 2 diabetes. This immune response led to rapid insulin deficiency and was associated with insulin antibodies and allergies.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetology

Background:

  • Insulin therapy is common for diabetes management.
  • Immune responses to insulin are known but typically do not involve beta-cell destruction.
  • Previous literature lacks reports of insulin triggering pancreatic beta-cell destruction in diabetic patients.

Observation:

  • Three patients with long-standing type 2 diabetes or impaired glucose tolerance developed rapid C-peptide decline after initiating human insulin therapy.
  • These patients exhibited high insulin antibody titers and, in some cases, insulin allergy.
  • Histological examination revealed islet mononuclear cell infiltration in one patient.

Findings:

  • Human insulin administration appeared to trigger autoimmune pancreatic beta-cell destruction in susceptible individuals.
  • The destruction was characterized by a rapid loss of endogenous insulin production (C-peptide).
  • Genetic predisposition (HLA class II haplotype, insulin gene VNTR) was noted in the affected patients.

Implications:

  • Insulin therapy might induce or exacerbate autoimmune destruction in specific diabetic patient populations.
  • This phenomenon could represent a novel mechanism contributing to type 1 diabetes development or progression.
  • Further research is needed to identify at-risk individuals and explore preventative strategies.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...